- Nachrichtendetail
-
09.05.2024 14:39:06 - dpa-AFX: *MERCK : PHASE 3 TRIAL OF KEYTRUDA PLUS CHEMOTHERAPY IN ENDOMETRIAL CANCER FAILS TO MEET MAIN GOAL
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Merck & Co | A0YD8Q | NYSE | 129,450 | 05.06.24 22:00:06 | +0,740 | +0,57% | 128,500 | 129,970 | 128,480 | 128,710 |
